Evidence map›Paper›PMID 31563626›Full record

ReviewGastroenterology2020

Chemoprevention of Colorectal Cancer.

Bryson W Katona, Jennifer M Weiss

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 4 syntheses or guidelines pooled it, 194 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Eradication ofHealth technology assessment (Winchester, England) · 2025
    Trial
  8. Review
  9. Review
  10. Article
  11. Validation of a Colorectal Cancer Risk Prediction Model in US Black Women.Cancer prevention research (Philadelphia, Pa.) · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bryson W KatonaDivision of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Jennifer M WeissDivision of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: jmw@medicine.wisc.edu.
University of Pennsylvania · USUniversity of Wisconsin–Madison · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Menin/MLL promotes cell survival in the setting of EGFR inhibitionK08DK106489 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KATONA, BRYSON WILLIAM · 2015 to 2019
$819k
NCATS NIH HHS UL1 TR002373NIDDK NIH HHS K08 DK106489
6 · The paper itself

Abstract

Although colorectal cancer (CRC) screening has reduced the incidence of and mortality from CRC, chemoprevention strategies have the potential to further reduce CRC incidence and mortality. Chemoprevention agents might be used for average-risk as well as high-risk groups, and to prevent CRC recurrence after therapy. CRC chemoprevention agents that have been studied include aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, statins, agents that target metabolic pathways, and vitamins and minerals. We review the prospect of chemoprevention of CRC, results from preclinical and human studies, challenges, and future directions.

Indexed as

AnimalsAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalColorectal NeoplasmsDisease Models, AnimalDrug ApprovalDrug Evaluation, PreclinicalEarly Detection of CancerHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMass ScreeningPatient Acceptance of Health CareRandomized Controlled Trials as TopicTreatment OutcomeUnited StatesAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalHydroxymethylglutaryl-CoA Reductase InhibitorsVitaminsAdenomaChemopreventionColorectal Cancer

Identifiers

PMID31563626
PMCPMC6981249
OpenAlexW2976380466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.